Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 15/20 | 0.86 |
| ▸ | DAGLB | Q8NCG7 | 3/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297125 | 0.93 | DAGLA (1.00) | DAGLADAGLBNR1I2CYP3A4CYP2D6 | |
| SCHEMBL2297110 | 0.90 | DAGLA (1.00) | DAGLADAGLBNR1I2CYP3A4CYP2D6 | |
| SCHEMBL2299131 | 0.89 | DAGLA (1.00) | DAGLADAGLBNR1I2CYP3A4CYP2D6 | |
| SCHEMBL2303720 | 0.87 | DAGLA (1.00) | DAGLADAGLBNR1I2CYP3A4CYP2D6 | |
| SCHEMBL2297486 | 0.85 | DAGLA (0.78) | DAGLADAGLBNR1I2CYP3A4CYP2D6 | |
| SCHEMBL2343368 | 0.84 | DAGLA (1.00) | DAGLADAGLBNR1I2CYP3A4CYP2D6 | |
| SCHEMBL12391521 | 0.82 | DAGLA (0.82) | DAGLADAGLBNR1I2CYP3A4CYP2D6 | |
| SCHEMBL2300570 | 0.81 | DAGLA (1.00) | DAGLADAGLBNR1I2CYP3A4CYP2D6 | |
| SCHEMBL2296498 | 0.80 | DAGLA (1.00) | DAGLADAGLBNR1I2CYP3A4CYP2D6 | |
| SCHEMBL6864007 | 0.80 | DAGLA (0.82) | DAGLADAGLBNR1I2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536694-B1 | Glycine sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL MYERS SQUIBB CO (US) | 2014-01-22 | — | — | EP | claimed |
| US-8404741-B2 | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | claimed |
| US-20110207749-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-25 | — | — | US | claimed |
| EP-2536694-B1 | Glycine sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL MYERS SQUIBB CO (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2536694-B1 | Glycine sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL MYERS SQUIBB CO (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8404741-B2 | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404741-B2 | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404741-B2 | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| EP-2536694-A1 | GLYCINE SULFONAMIDES FOR USE AS INHIBITORS OF DIACYLGLYCEROL LIPASE | Bristol-Myers Squibb Company (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20110207749-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-25 | — | — | US | disclosed |
| US-20110207749-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-25 | — | — | US | disclosed |
| US-20110207749-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-25 | — | — | US | disclosed |
| WO-2011103055-A1 | GLYCINE SULFONAMIDES FOR USE AS INHIBITORS OF DIACYLGLYCEROL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011103055-A1 | GLYCINE SULFONAMIDES FOR USE AS INHIBITORS OF DIACYLGLYCEROL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207749-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | DAGLB, DAGLA, MGLL | DAGLA 2/4885DAGLB 1/4885NR1I2 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.